Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of What is the Link between Lung Involvement and Anti-CCP Antibodies in Rheumatoid Arthritis: A Cross-sectional Study

Abstract

Background

In Rheumatoid Arthritis (RA), pulmonary involvement is one of the most frequent extra-articular manifestations. Several studies have demonstrated an association between RA-related lung disease and the positivity of anti-cyclic citrullinated peptide (anti-CCP) antibodies.

Objective

Our aim is to describe the frequency of pulmonary involvement in the RA population and investigate the association between anti-CCP antibodies and diverse lung compartment involvement in RA patients.

Methods

An observational retrospective cross-sectional study was conducted, during which data were collected from the medical records of the patients with RA who had been tested for anti-CCP antibodies and had thoracic high resolution computerized tomography (HRCT) evaluation from January 2011 to March 2022. The univariate and multivariate analyses using logistic regression models was performed to calculate odds ratios (ORs) with 95% CIs.

Results

A total of 390 patients with RA were included, the mean age of patients was 58.99 ± 12.44 years, with a predominance of females (85.9%). Two hundred and fifty-two (64.6%) patients were positive for anti-CCP antibodies. The frequency of RA-related lung diseases was 14.4% (n=56). The different manifestations observed in the thoracic HRCT included Nodules (67.9%), Interstitial lung disease (ILD) (28.6%), bronchiectasis (25%), fibrosis (21.4%), obliterative bronchiolitis (7.1%), and pleuritis (1.8%). In univariate and multivariate analysis, pulmonary involvement was associated with positive anti-CCP antibodies with an odds ratio (OR) of 5.25 (95% CI: 2.17-12.70, < 0.0001).

Conclusion

The study demonstrated a positive association between anti-CCP antibodies and pulmonary involvement in RA and highlighted the importance of tight monitoring in RA patients with positive anti-CCP for pulmonary complications.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971298865240812063200
2024-09-12
2024-11-23

  • From This Site

    /content/journals/crr/10.2174/0115733971298865240812063200
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bullock J. Rizvi S.A.A. Saleh A.M. Ahmed S.S. Do D.P. Ansari R.A. Ahmed J. Rheumatoid Arthritis: A brief overview of the treatment. Med. Princ. Pract. 2018 27 6 501 507 10.1159/000493390 30173215
    [Google Scholar]
  2. Young A. Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007 21 5 907 927 10.1016/j.berh.2007.05.007 17870035
    [Google Scholar]
  3. Khan T. Jose R.J. Renzoni E.A. Mouyis M. A closer look at the role of anti-CCP antibodies in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and bronchiectasis. Rheumatol. Ther. 2021 8 4 1463 1475 10.1007/s40744‑021‑00362‑4 34449068
    [Google Scholar]
  4. Gauhar U. Gaffo A. Alarcón G. Pulmonary manifestations of rheumatoid arthritis. Semin. Respir. Crit. Care Med. 2007 28 4 430 440 10.1055/s‑2007‑985664 17764060
    [Google Scholar]
  5. Juge P.A. Granger B. Debray M.P. Ebstein E. Louis-Sidney F. Kedra J. Doyle T.J. Borie R. Constantin A. Combe B. Flipo R.M. Mariette X. Vittecoq O. Saraux A. Carvajal-Alegria G. Sibilia J. Berenbaum F. Kannengiesser C. Boileau C. Sparks J.A. Crestani B. Fautrel B. Dieudé P. A risk score to detect subclinical rheumatoid arthritis–associated interstitial lung disease. Arthritis Rheumatol. 2022 74 11 1755 1765 10.1002/art.42162 35583934
    [Google Scholar]
  6. Juge P.A. Lee J.S. Ebstein E. Furukawa H. Dobrinskikh E. Gazal S. Kannengiesser C. Ottaviani S. Oka S. Tohma S. Tsuchiya N. Rojas-Serrano J. González-Pérez M.I. Mejía M. Buendía-Roldán I. Falfán-Valencia R. Ambrocio-Ortiz E. Manali E. Papiris S.A. Karageorgas T. Boumpas D. Antoniou K. van Moorsel C.H.M. van der Vis J. de Man Y.A. Grutters J.C. Wang Y. Borie R. Wemeau-Stervinou L. Wallaert B. Flipo R.M. Nunes H. Valeyre D. Saidenberg-Kermanac’h N. Boissier M.C. Marchand-Adam S. Frazier A. Richette P. Allanore Y. Sibilia J. Dromer C. Richez C. Schaeverbeke T. Lioté H. Thabut G. Nathan N. Amselem S. Soubrier M. Cottin V. Clément A. Deane K. Walts A.D. Fingerlin T. Fischer A. Ryu J.H. Matteson E.L. Niewold T.B. Assayag D. Gross A. Wolters P. Schwarz M.I. Holers M. Solomon J.J. Doyle T. Rosas I.O. Blauwendraat C. Nalls M.A. Debray M.P. Boileau C. Crestani B. Schwartz D.A. Dieudé P. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N. Engl. J. Med. 2018 379 23 2209 2219 10.1056/NEJMoa1801562 30345907
    [Google Scholar]
  7. Li L. Liu R. Zhang Y. Zhou J. Li Y. Xu Y. Gao S. Zheng Y. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin. Rheumatol. 2020 39 5 1457 1470 10.1007/s10067‑019‑04846‑1 31858341
    [Google Scholar]
  8. Choi WI Dauti S Kim HJ Park SH Park JS Lee CW Risk factors for interstitial lung disease: A 9-year Nationwide population-based study. BMC Pulmonary Med 2018 18 96 0660 10.1186/s12890‑018‑0660‑2
    [Google Scholar]
  9. Oka S Higuchi T Furukawa H Serum rheumatoid factor IgA, anti-citrullinated peptide antibodies with secretory components, and anti-carbamylated protein antibodies associate with interstitial lung disease in rheumatoid arthritis. BMC Musculoskelet Disord. 2022 23 46 10.1186/s12891‑021‑04985‑0
    [Google Scholar]
  10. Perry E. Kelly C. Eggleton P. De Soyza A. Hutchinson D. The lung in ACPA-positive rheumatoid arthritis: An initiating site of injury? Rheumatology (Oxford) 2014 53 11 1940 1950 10.1093/rheumatology/keu195 24831057
    [Google Scholar]
  11. Haj Hensvold A. Magnusson P.K.E. Joshua V. Hansson M. Israelsson L. Ferreira R. Jakobsson P.J. Holmdahl R. Hammarström L. Malmström V. Askling J. Klareskog L. Catrina A.I. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: An epidemiological investigation in twins. Ann. Rheum. Dis. 2015 74 2 375 380 10.1136/annrheumdis‑2013‑203947 24276366
    [Google Scholar]
  12. Zhang M Yin J Zhang X Factors associated with interstitial lung disease in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS One 2023 18 6 e0286191 10.1371/journal.pone.0286191
    [Google Scholar]
  13. Arnett F.C. Edworthy S.M. Bloch D.A. Mcshane D.J. Fries J.F. Cooper N.S. Healey L.A. Kaplan S.R. Liang M.H. Luthra H.S. Medsger T.A. Jr Mitchell D.M. Neustadt D.H. Pinals R.S. Schaller J.G. Sharp J.T. Wilder R.L. Hunder G.G. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 31 3 315 324 10.1002/art.1780310302 3358796
    [Google Scholar]
  14. Aletaha D. Neogi T. Silman A.J. Funovits J. Felson D.T. Bingham C.O. III Birnbaum N.S. Burmester G.R. Bykerk V.P. Cohen M.D. Combe B. Costenbader K.H. Dougados M. Emery P. Ferraccioli G. Hazes J.M.W. Hobbs K. Huizinga T.W.J. Kavanaugh A. Kay J. Kvien T.K. Laing T. Mease P. Ménard H.A. Moreland L.W. Naden R.L. Pincus T. Smolen J.S. Stanislawska-Biernat E. Symmons D. Tak P.P. Upchurch K.S. Vencovský J. Wolfe F. Hawker G. 2010 rheumatoid arthritis classification criteria: An american college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum. 2010 62 9 2569 2581 10.1002/art.27584 20872595
    [Google Scholar]
  15. Prevoo M.L.L. Van’T Hof M.A. Kuper H.H. Van Leeuwen M.A. Van De Putte L.B.A. Van Riel P.L.C.M. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 38 1 44 48 10.1002/art.1780380107 7818570
    [Google Scholar]
  16. Duarte A.C. Porter J.C. Leandro M.J. The lung in a cohort of rheumatoid arthritis patients—an overview of different types of involvement and treatment. Rheumatology (Oxford) 2019 58 11 2031 2038 10.1093/rheumatology/kez177 31089697
    [Google Scholar]
  17. Dahani A Aamer N Seerani NL Karim MT Khan F Arain SR Pulmonary manifestations in patients with rheumatoid arthritis visiting tertiary care hospital. J Ayub Med Coll Abbottabad 2022 34 Suppl 1 S991 S994 10.55519/JAMC‑04‑S4‑9714
    [Google Scholar]
  18. Bilgici A. Ulusoy H. Kuru O. Çelenk Ç. Ünsal M. Danacı M. Pulmonary involvement in rheumatoid arthritis. Rheumatol. Int. 2005 25 6 429 435 10.1007/s00296‑004‑0472‑y 16133582
    [Google Scholar]
  19. Huang S. Kronzer V.L. Dellaripa P.F. Deane K.D. Bolster M.B. Nagaraja V. Khanna D. Doyle T.J. Sparks J.A. Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. Curr. Treatm. Opt. Rheumatol. 2020 6 4 337 353 10.1007/s40674‑020‑00160‑z 33282632
    [Google Scholar]
  20. Bergström U. Jacobsson L.T.H. Nilsson J.A. Berglund G. Turesson C. Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology (Oxford) 2011 50 11 2005 2013 10.1093/rheumatology/ker258 21859698
    [Google Scholar]
  21. Richman N.C. Yazdany J. Graf J. Chernitskiy V. Imboden J.B. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore) 2013 92 2 92 97 10.1097/MD.0b013e318289ce01 23429352
    [Google Scholar]
  22. Salaffi F. Carotti M. Di Carlo M. Tardella M. Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis. Medicine (Baltimore) 2019 98 38 e17088 10.1097/MD.0000000000017088 31567944
    [Google Scholar]
  23. Chen J. Shi Y. Wang X. Huang H. Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin. Dev. Immunol. 2013 2013 1 5 10.1155/2013/406927 23983768
    [Google Scholar]
  24. Giles J.T. Danoff S.K. Sokolove J. Wagner C.A. Winchester R. Pappas D.A. Siegelman S. Connors G. Robinson W.H. Bathon J.M. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann. Rheum. Dis. 2014 73 8 1487 1494 10.1136/annrheumdis‑2012‑203160 23716070
    [Google Scholar]
  25. Yin Y Liang D Zhao L Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One 2014 9 4 e92449 10.1371/journal.pone.0092449
    [Google Scholar]
  26. Fischer A. Solomon J.J. du Bois R.M. Deane K.D. Olson A.L. Fernandez-Perez E.R. Huie T.J. Stevens A.D. Gill M.B. Rabinovitch A.M. Lynch D.A. Burns D.A. Pineiro I.S. Groshong S.D. Duarte Achcar R.D. Brown K.K. Martin R.J. Swigris J.J. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir. Med. 2012 106 7 1040 1047 10.1016/j.rmed.2012.03.006 22503074
    [Google Scholar]
  27. Katsumata M. Hozumi H. Yasui H. Suzuki Y. Kono M. Karayama M. Furuhashi K. Enomoto N. Fujisawa T. Inui N. Nakamura Y. Suda T. Frequency and clinical relevance of anti-cyclic citrullinated peptide antibody in idiopathic interstitial pneumonias. Respir. Med. 2019 154 102 108 10.1016/j.rmed.2019.06.016 31229943
    [Google Scholar]
  28. Kamiya H Panlaqui OM Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open 2021 1 3 e040465 10.1136/bmjopen‑2020‑040465
    [Google Scholar]
  29. Alunno A. Bistoni O. Pratesi F. La Paglia G.M.C. Puxeddu I. Migliorini P. Gerli R. Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2018 57 5 850 855 10.1093/rheumatology/kex520 29452423
    [Google Scholar]
  30. Liu Y. Liu C. Li L. Zhang F. Li Y. Zhang S. High levels of antibodies to citrullinated α-enolase peptide-1 (CEP-1) identify erosions and interstitial lung disease (ILD) in a Chinese rheumatoid arthritis cohort. Clin. Immunol. 2019 200 10 15 10.1016/j.clim.2019.01.001 30611755
    [Google Scholar]
  31. Liao K.P. Sparks J.A. Hejblum B.P. Kuo I.H. Cui J. Lahey L.J. Cagan A. Gainer V.S. Liu W. Cai T.T. Sokolove J. Cai T. Phenome-wide association study of autoantibodies to citrullinated and noncitrullinated epitopes in rheumatoid arthritis. Arthritis Rheumatol. 2017 69 4 742 749 10.1002/art.39974 27792870
    [Google Scholar]
  32. England B.R. Duryee M.J. Roul P. Mahajan T.D. Singh N. Poole J.A. Ascherman D.P. Caplan L. Demoruelle M.K. Deane K.D. Klassen L.W. Thiele G.M. Mikuls T.R. Malondialdehyde–acetaldehyde adducts and antibody responses in rheumatoid arthritis–associated interstitial lung disease. Arthritis Rheumatol. 2019 71 9 1483 1493 10.1002/art.40900 30933423
    [Google Scholar]
  33. Harlow L. Rosas I.O. Gochuico B.R. Mikuls T.R. Dellaripa P.F. Oddis C.V. Ascherman D.P. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013 65 4 869 879 10.1002/art.37881 23400887
    [Google Scholar]
  34. Kronzer V.L. Hayashi K. Yoshida K. Davis J.M. III McDermott G.C. Huang W. Dellaripa P.F. Cui J. Feathers V. Gill R.R. Hatabu H. Nishino M. Blaustein R. Crowson C.S. Robinson W.H. Sokolove J. Liao K.P. Weinblatt M.E. Shadick N.A. Doyle T.J. Sparks J.A. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case–control study. Lancet Rheumatol. 2023 5 2 e77 e87 10.1016/S2665‑9913(22)00380‑0 36874209
    [Google Scholar]
  35. Joshua V. Hensvold A.H. Reynisdottir G. Hansson M. Cornillet M. Nogueira L. Serre G. Nyren S. Karimi R. Eklund A. Sköld M. Grunewald J. Chatzidionysiou K. Catrina A. Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis. RMD Open 2020 6 2 e001278 10.1136/rmdopen‑2020‑001278 32917833
    [Google Scholar]
  36. Xie S. Li S. Chen B. Zhu Q. Xu L. Li F. Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis–related interstitial lung disease: A meta-analysis. Clin. Rheumatol. 2021 40 11 4533 4543 10.1007/s10067‑021‑05808‑2 34189672
    [Google Scholar]
  37. Shidara K. Hoshi D. Inoue E. Yamada T. Nakajima A. Taniguchi A. Hara M. Momohara S. Kamatani N. Yamanaka H. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod. Rheumatol. 2010 20 3 280 286 10.3109/s10165‑010‑0280‑z 20217173
    [Google Scholar]
  38. Paulin F. Doyle T.J. Mercado J.F. Fassola L. Fernández M. Caro F. Alberti M.L. Espíndola M.E.C. Buschiazzo E. Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis. Reumatología Clínica (English Edition) 2021 17 4 207 211 10.1016/j.reumae.2019.05.006 31420237
    [Google Scholar]
  39. Severo C.R. Chomiski C. Valle M.B.D. Escuissato D.L. Paiva E.D.S. Storrer K.M. Assessment of risk factors in patients with rheumatoid arthritis-associated interstitial lung disease. J. Bras. Pneumol. 2022 48 6 e20220145 10.36416/1806‑3756/e20220145 36477171
    [Google Scholar]
  40. Kiely P Busby AD Nikiphorou E Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 2019 9 5 e028466 10.1136/bmjopen‑2018‑028466
    [Google Scholar]
  41. Conway R Low C Coughlan RJ O'Donnell MJ Carey JJ Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: Systematic literature review and meta-analysis of randomised controlled trials. BMJ 2015 350 5 h1269 10.1136/bmj.h1269
    [Google Scholar]
  42. Narváez J. Aburto M. Seoane-Mato D. Bonilla G. Acosta O. Candelas G. Cano-Jiménez E. Castellví I. González-Ruiz J.M. Corominas H. López-Muñiz B. Martín-López M. Robles-Pérez A. Mena-Vázquez N. Rodríguez-Portal J.A. Ortiz A.M. Sabater-Abad C. Castrejón I. dos Santos R. Garrote-Corral S. Maese J. Silva-Fernández L. Castañeda S. Valenzuela C. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology. Reumatología Clínica (English Edition) 2023 19 2 74 81 10.1016/j.reumae.2021.12.003 35753951
    [Google Scholar]
/content/journals/crr/10.2174/0115733971298865240812063200
Loading
What is the Link between Lung Involvement and Anti-CCP Antibodies in Rheumatoid Arthritis: A Cross-sectional Study
Bentham Science Publishers ; https://doi.org/10.2174/0115733971298865240812063200
/content/journals/crr/10.2174/0115733971298865240812063200
/content/journals/crr/10.2174/0115733971298865240812063200
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Anti-cyclic citrullinated peptide antibodies ; smoking ; thoracichigh-resolution computerized tomography ; ILD ; rheumatoid arthritis ; methotrexate ; pulmonary involvement ; lung

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test